Logo Prima Biomed

Overview

Current IMP321 Clinical Trials

Product Phase Protocol Population Patients Status

IMP321 in chemoimmunotherapy

IIb AIPAC Metastatic Breast Cancer 226 Recruiting

IMP321 in immuno-oncology combination

I TACTI-mel Metastatic Melanoma 18 Recruiting

Completed IMP321 Clinical Trials

Product Phase Protocol Population Patients Status

IMP321 as adjuvant

I P001 Healthy Volunteers with influenza antigen 60 Completed

IMP321 as adjuvant

I P002 Healthy Volunteers with hepatitis antigen 50 Completed

IMP321 as monotherapy

I P003 Stage IV Renal Cell Carcinoma 21 Completed

IMP321 as chemoimmunotherapy

I P005 Metastatic Breast Cancer 33 Completed

IMP321 as adjuvant

I/ II P006

Disease-free Melanoma

22 Completed

IMP321 as adjuvant

I P007
Metastatic Melanoma 12 Completed

IMP321 as chemoimmunotherapy

I

P008

Advanced Pancreatic Cancer

17 Completed

IMP321 as adjuvant

I/ IIa P009 Metastatic Melanoma 16 Completed

IMP321 as adjuvant

II P010 Prostate Carcinoma 20 Completed